(0.26%) 5 535.75 points
(0.25%) 39 568 points
(0.26%) 19 979 points
(0.64%) $82.06
(-1.81%) $2.55
(0.35%) $2 347.70
(0.14%) $29.60
(-0.70%) $994.90
(-0.25%) $0.931
(-0.30%) $10.64
(-0.17%) $0.789
(2.09%) $87.52
Live Chart Being Loaded With Signals
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally...
Stats | |
---|---|
今日成交量 | 10.20M |
平均成交量 | 1.85M |
市值 | 236.70M |
EPS | $-0.170 ( Q1 | 2024-05-07 ) |
下一个收益日期 | ( $-0.110 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.78 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.00700 (0.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Morris Timothy E | Buy | 38 000 | Stock Option (right to purchase) |
2024-06-20 | Taglietti Marco | Buy | 38 000 | Stock Option (Right to Purchase) |
2024-06-20 | Brown Gregory B | Buy | 38 000 | Stock Option (Right to Purchase) |
2024-06-20 | Krop Julie | Buy | 38 000 | Stock Option (Right to Purchase) |
2024-06-20 | Cochran John | Buy | 38 000 | Stock Option (Right to Purchase) |
INSIDER POWER |
---|
87.07 |
Last 98 transactions |
Buy: 5 885 486 | Sell: 282 172 |
音量 相关性
Aquestive Therapeutics 相关性 - 货币/商品
Aquestive Therapeutics 财务报表
Annual | 2023 |
营收: | $50.58M |
毛利润: | $29.97M (59.25 %) |
EPS: | $-0.130 |
FY | 2023 |
营收: | $50.58M |
毛利润: | $29.97M (59.25 %) |
EPS: | $-0.130 |
FY | 2022 |
营收: | $47.68M |
毛利润: | $28.29M (59.34 %) |
EPS: | $-1.240 |
FY | 2021 |
营收: | $50.83M |
毛利润: | $50.83M (100.00 %) |
EPS: | $-2.10 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。